Hippo Pathway-independent Restriction of TAZ and YAP by Angiomotin

被引:316
|
作者
Chan, Siew Wee [1 ]
Lim, Chun Jye [1 ]
Chong, Yaan Fun [1 ]
Pobbati, Ajaybabu V. [1 ]
Huang, Caixia [1 ]
Hong, Wanjin [1 ,2 ]
机构
[1] Inst Mol & Cell Biol, Canc & Dev Cell Biol Div, Singapore 138673, Singapore
[2] Natl Univ Singapore, Dept Biochem, Singapore 119077, Singapore
关键词
YES-ASSOCIATED PROTEIN; EPITHELIAL-MESENCHYMAL TRANSITION; CELL CONTACT INHIBITION; ORGAN SIZE CONTROL; WW DOMAIN; ONCOGENIC TRANSFORMATION; GROWTH-CONTROL; TRANSCRIPTION; BINDING; CANCER;
D O I
10.1074/jbc.C110.212621
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The Hippo pathway restricts the activity of transcriptional co-activators TAZ and YAP by phosphorylating them for cytoplasmic sequestration or degradation. In this report, we describe an independent mechanism for the cell to restrict the activity of TAZ and YAP through interaction with angiomotin (Amot) and angiomotin-like 1 (AmotL1). Amot and AmotL1 were robustly co-immunoprecipitated with FLAG-tagged TAZ, and their interaction is dependent on the WW domain of TAZ and the PPXY motif in the N terminus of Amot. Amot and AmotL1 also interact with YAP via the first WW domain of YAP. Overexpression of Amot and AmotL1 caused cytoplasmic retention of TAZ and suppressed its transcriptional outcome such as the expression of CTGF and Cyr61. Hippo refractory TAZ mutant (S89A) is also negatively regulated by Amot and AmotL1. HEK293 cells express the highest level of Amot and AmotL1 among nine cell lines examined, and silencing the expression of endogenous Amot increased the expression of CTGF and Cyr61 either at basal levels or upon overexpression of exogenous S89A. These results reveal a novel mechanism to restrict the activity of TAZ and YAP through physical interaction with Amot and AmotL1.
引用
收藏
页码:7018 / 7026
页数:9
相关论文
共 50 条
  • [1] The Hippo Pathway, YAP/TAZ, and the Plasma Membrane
    Rausch, Valentina
    Hansen, Carsten G.
    TRENDS IN CELL BIOLOGY, 2020, 30 (01) : 32 - 48
  • [2] Angiomotin is a novel Hippo pathway component that inhibits YAP oncoprotein
    Zhao, Bin
    Li, Li
    Lu, Qing
    Wang, Lloyd H.
    Liu, Chen-Ying
    Lei, Qunying
    Guan, Kun-Liang
    GENES & DEVELOPMENT, 2011, 25 (01) : 51 - 63
  • [3] Role of Hippo Pathway-YAP/TAZ Signaling in Angiogenesis
    Boopathy, Gandhi T. K.
    Hong, Wanjin
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2019, 7
  • [4] Hippo pathway oncogenic effectors YAP and TAZ in cutaneous melanoma
    Nallet-Staub, F.
    Marsaud, V.
    Li, L.
    Gilbert, C.
    Dodier, S.
    Bataille, V.
    Sudol, M.
    Herlyn, M.
    Mauviel, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 : S231 - S231
  • [5] Control of skeletal morphogenesis by the Hippo-YAP/TAZ pathway
    Vanyai, Hannah K.
    Prin, Fabrice
    Guillermin, Oriane
    Marzook, Bishara
    Boeing, Stefan
    Howson, Alexander
    Saunders, Rebecca E.
    Snoeks, Thomas
    Howell, Michael
    Mohun, Timothy J.
    Thompson, Barry
    DEVELOPMENT, 2020, 147 (21):
  • [6] The Roles of YAP/TAZ and the Hippo Pathway in Healthy and Diseased Skin
    Rognoni, Emanuel
    Walko, Gernot
    CELLS, 2019, 8 (05)
  • [7] Hippo pathway effectors YAP/TAZ as novel determinants of ferroptosis
    Yang, Wen-Hsuan
    Chi, Jen-Tsan
    MOLECULAR & CELLULAR ONCOLOGY, 2020, 7 (01)
  • [8] Characterization of the Hippo Pathway in Melanoma: Focus on the effectors YAP and TAZ
    Nallet-Staub, F.
    Gilbert, C.
    Dodier, S.
    Bataille, V.
    Sudol, M.
    Li, L.
    Herlyn, M.
    Mauviel, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2012, 132 : S128 - S128
  • [9] The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease
    Varelas, Xaralabos
    DEVELOPMENT, 2014, 141 (08): : 1614 - 1626
  • [10] The regulation of Yorkie, YAP and TAZ: new insights into the Hippo pathway
    Manning, Samuel A.
    Kroeger, Benjamin
    Harvey, Kieran F.
    DEVELOPMENT, 2020, 147 (08):